IN8bio jumps on positive results from early-stage leukemia trial

IN8bio

24/04/2023 14:41

** Shares of drug developer IN8bio Inc  INAB.O  surge 134.4%
to $2.46
    ** Co announced positive new data from early-stage
investigator-sponsored trial of INB-100 in leukemia patients
    ** Data showed 100% of evaluable patients treated with
INB-100 remained alive, progression-free, and in durable
complete remission
    ** The trial is being expanded at Dose Level 2, and
additional patients are actively being enrolled and treated in
the study - INAB
    ** Despite session gains, stock down ~54% YTD

 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))